We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Preventing Unnecessary Radiotherapy for Patients with Early-Stage Hodgkin’s Lymphoma

By MedImaging International staff writers
Posted on 27 Apr 2015
Print article
Image: PET scan images (Courtesy of King’s College London).
Image: PET scan images (Courtesy of King’s College London).
A new study suggested that patients with early-stage (stage 1a or 2a) Hodgkin’s lymphoma disease, who underwent three cycles of chemotherapy with the drugs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), and presented negative findings from Positron-Emission Tomography (PET), did not need additional field radiotherapy.

The study data was provided by a UK National Cancer Research Institute trial led by the University of Manchester (Manchester, UK) and the Christie NHS Foundation Trust, and published in the April 23, 2015, edition of the New England Journal of Medicine (NEJM).

The study included a total of 602 patients. PET scanning revealed that the findings were negative in 426 patients. 209 of these patients received radiotherapy, and 211 patients received no further treatment. Patients in both groups were monitored for a period of 5 years.

The results of the study showed that patients with early-stage Hodgkin’s lymphoma who presented with negative PET findings, and had completed three cycles of chemotherapy had a very good prognosis either with or without consolidation radiotherapy. The survival rate of the group of 211 patients that received no further treatment was 90.8%.

Leader researcher of the study, Prof. John Radford, based at the University of Manchester, said, “This research is an important step forward. The results of RAPID show that in early stage Hodgkin lymphoma radiotherapy after initial chemotherapy marginally reduces the recurrence rate, but this is bought at the expense of exposing to radiation all patients with negative PET findings, most of whom are already cured.”

Related Links:

University of Manchester 


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
MRI System
uMR 588
Compact C-Arm with FPD
Arcovis DRF-C R21
New
Computed Tomography (CT) Scanner
Aquilion Serve SP

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.